ClinicalTrials.gg
RecruitingNCT07439757Updated Feb 27, 2026

AI-Powered Precision Decision-Making for Pancreatic Diseases

An observational study in Pancreatic Cancer, Diagnose Disease and IPMN, Pancreatic, sponsored by Changhai Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-02-27.

Primary conditionPancreatic Intraductal NeoplasmsRegistry: Pancreatic NeoplasmsReclassifiedWhy we changed it
Registry
Pancreatic Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Pancreatic Intraductal Neoplasms
Why
  1. The study's listed conditions name Pancreatic Intraductal Neoplasms, a narrower term within Pancreatic Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Changhai Hospital · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,000
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This multicenter clinical trial evaluates an artificial intelligence (AI) system designed to assist in the diagnosis and management of pancreatic diseases. Using contrast-enhanced CT scans, the study compares the AI's recommendations against the decisions of experienced clinicians to verify the system's accuracy and safety in a real-world setting. Patients are categorized into three management groups: Intervention (surgery/treatment), Intensive Surveillance (close monitoring), or Routine Surveillance (standard follow-up). The primary goal is to determine if the AI system can reliably classify patients, reduce the risk of missing malignant lesions, and prevent unnecessary surgeries, thereby improving clinical decision-making for pancreatic conditions.

Read the detailed description

MEHTOD: This multicenter clinical trial evaluates the reliability and effectiveness of an AI system for patients with pancreatic diseases in a real-world clinical environment. The study calculates the AI system's classification accuracy using pathological diagnosis (biopsy/surgery results) or long-term follow-up as the "gold standard" for comparison. Additionally, the safety and clinical utility of the management strategies recommended by the AI are assessed by measuring the risk of missing malignant lesions, the rate of unnecessary surgeries for pancreatic diseases, and the level of agreement with traditional clinical decisions.

STUDY DESIGN

All contrast-enhanced CT images from patients with pancreatic diseases are analyzed by the AI system to generate a classification result (Intervention, Intensive Surveillance, or Routine Surveillance). Simultaneously, clinical doctors review the same data and categorize patients into these three groups to determine their actual care plan:

  1. INTERVENTION: Patients assessed by doctors as needing "Intervention" are recommended for further surgical evaluation or treatment.
  2. INTENSIVE SURVEILLANCE: Patients assessed by doctors as needing "Intensive Surveillance" receive a personalized, high-frequency follow-up plan until the study endpoint.
  3. ROUTINE SURVEILLANCE: Patients assessed by doctors as needing "Routine Surveillance" undergo follow-up for at least one year. If abnormalities arise during this period, the patient is transferred to the appropriate "Intervention" or "Intensive Surveillance" protocol.

OUTCOMES: The study compares the performance of the AI system against clinical doctors regarding classification accuracy, the risk of missed diagnoses, unnecessary surgery rates, and decision consistency. These metrics are used to validate the AI system's value, safety, and utility in the clinical management of pancreatic diseases.

02

Conditions studied

  • Pancreatic Cancer
  • Diagnose Disease
  • IPMN, Pancreatic
  • Pancreatic Cystic Lesions
  • Chronic Pancreatitis
  • Pancreatic Neuroendocrine Tumor
  • Acute Pancreatitis (AP)

Keywords

  • Artificial Intelligence (AI), Deep Learning, Contrast-Enhanced CT, Multicenter Clinical Trial, Real-World Study
03

In context

Pancreatic Intraductal Neoplasms Reclassified

32 studies on the registry are indexed under Pancreatic Intraductal Neoplasms; 21 are open to participants now.

This study's planned enrollment of 2,000 is above the median of 586 across 17 observational studies indexed under Pancreatic Intraductal Neoplasms.

Browse Pancreatic Intraductal Neoplasms studies →

Lead sponsor

Changhai Hospital is the lead sponsor of 355 studies on the registry; 136 are open to participants now.

Compared within Pancreatic Intraductal Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Pancreatic Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study enrolls patients with clinically suspected pancreatic disease who have available contrast-enhanced CT scans and provide informed consent. Patients are excluded if they have a history of pancreatic surgery, contraindications to contrast media, suboptimal image quality, or other conditions deemed unsuitable by the investigator (e.g., pregnancy, cognitive impairment, or concurrent trial participation).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinically suspected pancreatic disease.
  • Scheduled to undergo contrast-enhanced CT.
  • Signed form indicating agreement to participate.

Exclusion criteria

Exclusion Criteria:

  • History of pancreatic surgery.
  • to contrast-enhanced CT, including known to iodinated contrast media or severe renal/hepatic dysfunction.
  • Suboptimal image quality affecting diagnosis.
  • Concurrent participation in another interventional clinical trial.
  • Unsuitability for participation as determined by the investigator, including but not limited to: pregnancy or lactation, severe psychiatric disorders or cognitive impairment, significant comorbidities that may interfere with study results or patient safety.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,000 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes

Groups and cohorts

  • AI group

    Diagnosis by Artificial Intelligence model

    Diagnostic Test: Diagnosis by Artificial Intelligence model

  • Clinicians group

    Diagnosis by clinicians

Interventions

  • Diagnostic testDiagnosis by Artificial Intelligence model

    To develop an artificial intelligence-based classification management system for pancreatic diseases, achieving automated and precise classification. Contrast-enhanced CT images from all study subjects will be analyzed by the AI system to generate classification results, categorizing patients into three groups: INTERVENTIOM, INTENSIVE SURVEILLANCE or ROUTINE SURVEILLANCE.

06

What researchers measure

Primary outcomes

  1. Classification accuracy

    The percentage of cases correctly classified by AI out of the total number of cases.

    Time frame: From date of contrast-enhanced CT scan to 1 year

Secondary outcomes

  1. Agreement rate with clinical decisions

    The proportion of total cases where AI and clinician classification results are in agreement.

    Time frame: From date of contrast-enhanced CT scan to 1 year

  2. Percentage decrease in unnecessary surgical procedures

    The percentage reduction in the unnecessary surgery rate achieved by AI decision-making compared to traditional decision-making.

    Time frame: From date of contrast-enhanced CT scan to 1 year

  3. Malignancy miss rate

    The proportion of cases classified by AI as non-surgical that actually required surgery.

    Time frame: From date of contrast-enhanced CT scan to 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2026; primary completion for Oct 2029, 43 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2026
First posted
Feb 27, 2026
StartEst.
Mar 1, 2026
Primary completionEst.
Oct 31, 2029
CompletionEst.
Oct 31, 2029
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07439757
Lead sponsor
Changhai Hospital
Collaborators
The First Affiliated Hospital with Nanjing Medical University, The Affiliated People's Hospital of Ningbo University, The Second Affiliated Hospital of Jiaxing University, Shanghai Changzheng Hospital, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shengjing Hospital, Shanghai Fourth People's Hospital Tongji University, The First Affiliated Hospital of Medical School of Zhejiang University, Shanghai Fudan University Cancer Center
Responsible party
Sponsor
First posted
Feb 27, 2026
Start date
Mar 1, 2026 (estimated)
Primary completion
Oct 31, 2029 (estimated)
Completion
Oct 31, 2029 (estimated)
Last update
Feb 27, 2026

Study contacts

Beilei Wang, Doctor
Contact
lilly_wang@126.com
+86 13774238083

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion